Martin Olin
![](https://mb.cision.com/Public/15728/0/a7817108406b61bf_800x800ar.jpg)
Photographer: Teresa Walton
Picture of Martin Olin CEO BerGenBioPhotographer: Teresa Walton
Picture of Martin Olin CEO BerGenBioBerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.